MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Feb 4 closing price
Price
$33.12
Change
+$0.24 (+0.73%)
Capitalization
9.46B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EXEL with price predictions
Feb 04, 2025

EXEL's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for EXEL moved out of overbought territory on January 16, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on January 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

EXEL moved below its 50-day moving average on January 22, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EXEL crossed bearishly below the 50-day moving average on January 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

EXEL broke above its upper Bollinger Band on January 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EXEL entered a downward trend on January 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.156) is normal, around the industry mean (15.863). P/E Ratio (21.368) is within average values for comparable stocks, (89.961). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (1.849). EXEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.789) is also within normal values, averaging (271.343).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 16.55% to 39 cents per share on February 11

Exelixis EXEL Stock Earnings Reports
Q4'24
Est.
$0.39
Q3'24
Beat
by $0.13
Q2'24
Beat
by $0.53
Q1'24
Missed
by $0.06
Q4'23
Beat
by $0.10
The last earnings report on October 29 showed earnings per share of 46 cents, beating the estimate of 34 cents. With 1.55M shares outstanding, the current market capitalization sits at 9.46B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FNGG192.576.01
+3.22%
Direxion Daily NYSE FANG+ Bull 2X Shares
CBSE34.930.39
+1.13%
Clough Select Equity ETF
TSME37.910.33
+0.88%
Thrivent Small-Mid Cap Equity ETF
ILCV83.770.26
+0.31%
iShares Morningstar Value ETF
IGSB51.860.07
+0.14%
iShares 1-5 Year invmt Grd Corp Bd ETF

EXEL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.73%
SRPT - EXEL
36%
Loosely correlated
+0.24%
ALNY - EXEL
34%
Loosely correlated
-1.29%
TECH - EXEL
33%
Poorly correlated
+0.69%
MRSN - EXEL
32%
Poorly correlated
+7.00%
ORMP - EXEL
32%
Poorly correlated
+1.39%
More